SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4135)2/13/2016 8:41:51 PM
From: mulanoon2007  Respond to of 4474
 
Drucker reported PON was effective in some TKI-resistant pts who exhibited no kinase domain mutations. He implicated inhibition of microenvironmental FGF signaling via FGFR3. Both paracrine and autocrine (see fig 5). Although this system is different from mutated/amplified FGFR in solid tumors it at least establishes a pharmacological principle. The brighter side of the coin of a promiscuous molecule I suppose.

ncbi.nlm.nih.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News